Zepbound vs Mounjaro for Weight Loss: Same Drug, Different Labels (May 2026)

Zepbound and Mounjaro are the same drug. They contain the same active ingredient, made by the same manufacturer, at the same doses. If you have seen both names and wondered which one actually works better for weight loss, the answer is neither — they are identical in the only way that matters clinically.

What differs is the FDA label, and that distinction has large downstream consequences for insurance, cost, and how your prescriber writes the prescription.

The molecule: tirzepatide

Both Zepbound and Mounjaro contain tirzepatide, a once-weekly injectable that acts on two hormone receptors simultaneously:

• GIP receptor (glucose-dependent insulinotropic polypeptide)
• GLP-1 receptor (glucagon-like peptide-1)

This dual agonism is what makes tirzepatide distinct from semaglutide (Ozempic/Wegovy), which targets the GLP-1 receptor alone. In the SURMOUNT-1 obesity trial, tirzepatide produced mean weight loss of up to 22.5% at 72 weeks on the 15 mg dose — among the highest outcomes seen for any approved anti-obesity medication. In the SURPASS T2D programme, weight loss was similarly substantial alongside A1C reduction.

The mechanism is the same whether the vial says Zepbound or Mounjaro.

Why two brand names exist

Eli Lilly obtained FDA approval for tirzepatide twice, for two different conditions:

The clinical trials behind each approval are different — SURPASS for Mounjaro's T2D data, SURMOUNT for Zepbound's obesity data — but the drug tested was the same compound throughout. This is standard pharmaceutical regulatory practice: the same molecule generates two commercial products, two FDA files, and two insurance formulary positions.

The same structure applies to semaglutide: Ozempic (T2D label) and Wegovy (obesity label) are also the same molecule under two names. For the tirzepatide vs semaglutide comparison, see mounjaro-vs-zepbound.

The insurance consequence

The label on your prescription determines how your insurer categorises the drug. That categorisation controls whether the drug is covered, at what copay tier, and under which prior-authorisation rules.

The Mounjaro Savings Card reduces cost to approximately $25/month for T2D patients with qualifying commercial insurance — it does not apply to Medicare, Medicaid, or Tricare. An equivalent Zepbound Savings Card exists for obesity-label patients with commercial coverage at the same copay level.

Which one should you get?

The answer depends on your clinical situation, not on any difference in the drug itself.

You have type 2 diabetes. Mounjaro is the correct label. Commercial insurance T2D coverage is generally the most accessible and lowest-cost path for tirzepatide. The Mounjaro Savings Card at roughly $25/month is significantly cheaper than any cash-pay route. You will still get the full weight-loss benefit of tirzepatide — the T2D trials showed average weight reductions of 16–22% — and you do not need the Zepbound label to access that effect.

You want weight loss without a T2D diagnosis. Zepbound is the correct label. This is what Zepbound was approved for. Whether your insurer covers it depends on your specific plan: roughly 49% of large employer plans covered obesity-indicated GLP-1s as of 2025, but many require prior authorisation, step therapy through cheaper medications first, and documented BMI or comorbidity criteria. See insurance coverage for GLP-1 drugs for what to expect in the PA process.

You have both T2D and obesity. You have a choice. For most patients, Mounjaro with T2D commercial coverage is cheaper and administratively simpler. Your prescriber may prefer one label depending on which condition is being managed as the primary diagnosis. Both are clinically valid.

You are paying cash. If you are self-paying and not running through insurance, the label distinction is mostly administrative. LillyDirect Self Pay offers tirzepatide (as Zepbound) at $299–$449/month depending on dose — see Zepbound cost breakdown for how those tiers work. No equivalent direct-purchase programme exists for Mounjaro vials. Cash-pay patients almost universally access tirzepatide through the Zepbound LillyDirect programme regardless of whether their clinical situation would technically match the Mounjaro label. For a full tirzepatide cash-pay map across all options, see tirzepatide cash price.

LillyDirect Self Pay: the cash-pay detail

As of May 2026, LillyDirect Self Pay prices for Zepbound are:

These prices apply to both single-dose vials and KwikPen since February 23, 2026. Vials require self-injection with a separate syringe; KwikPens are ready-to-use autoinjectors.

Enrolment is through LillyDirect — you need a valid prescription from a licensed prescriber. The programme is open to patients regardless of diagnosis. For enrolment steps, see LillyDirect Zepbound enrollment.

The off-label question

Prescribers can legally write Mounjaro for patients without T2D, and can write Zepbound for patients who have T2D. Off-label prescribing is common in medicine and is not inherently problematic.

The practical constraint is insurance. If a T2D patient has their Mounjaro covered under the diabetes benefit, writing Zepbound instead may require a different PA process under the obesity benefit — and may cost more or be denied. If a non-T2D patient receives a Mounjaro prescription, insurance will typically deny it and request a Zepbound prescription for the obesity indication.

The insurer is not making a clinical judgment. They are enforcing the indication-to-label matching that their formulary was built around.

Efficacy: identical

There is no clinical evidence that Zepbound and Mounjaro differ in weight-loss efficacy. They cannot — they are the same molecule at the same doses. Any comparison you read implying one performs better than the other is either comparing different doses or conflating the approved-population clinical trials (T2D vs obesity) rather than comparing the molecules.

The SURMOUNT trials enrolled patients with obesity but without T2D (or with T2D in SURMOUNT-2). The SURPASS trials enrolled T2D patients. Both show substantial weight loss. The obesity-labelled trial population started at higher body weight and saw higher absolute weight reduction, but this reflects trial design, not drug performance differences.

If you are choosing between Zepbound and Mounjaro for weight loss specifically because you believe one works better: they do not differ. The choice is entirely about coverage and cost.

Summary

Zepbound and Mounjaro are tirzepatide — the same GIP/GLP-1 dual agonist, the same dose range, made by Eli Lilly. The molecule is identical, the efficacy is the same, and the mechanism is the same.

The label determines:

• Which insurance benefit pays (diabetes vs obesity)
• What your copay will be
• Whether the savings card or LillyDirect programme applies
• What prior-authorisation pathway your prescriber navigates

For most patients: T2D diagnosis points to Mounjaro with commercial T2D coverage; weight loss without T2D points to Zepbound; cash-pay patients use LillyDirect Zepbound regardless of diagnosis.

The drug is the same. The paperwork is different.